Ceapro Inc. announced positive results from a research collaboration with the Angiogenesis Foundation conducted with colleagues at the University of Arizona. The aim of this study was to assess the in vivo bioactivity of Ceapro products on angiogenesis, wound healing, tissue repair, and regeneration. The study was based on key learnings from an earlier in vitro study where researchers from the Foundation demonstrated that Ceapro's AVE and BG stimulate proliferation of vascular endothelial cells (angiogenesis) which is a critical step in wound healing.

Results from the current in vivo study showed that both 1% AVE and 1% BG treatment resulted in earlier wound closure in mice compared to controls. Tissue analysis revealed that: 1% AVE treatment resulted in decreased tissue inflammation and the healed tissue had less scarring and an architecture more resembling normal tissue compared to that of scar tissue after control treatment. 1% BG-treated tissue exhibited more microvessels (angiogenesis) and the presence of endothelial progenitor cells, compared to control mice.

BG treatment also resulted in increased collagen fiber width and length, more resembling normal tissue architecture compared to scar tissue after control treatment. The researchers concluded that oat-based bioactives BG and AV exhibited potential to improve regenerative wound healing, reduce inflammation, promote angiogenesis, and reduce scar formation. These results will support additional claims for these products currently used in well-known cosmetic formulations while opening doors for Ceapro in the large and well-established wound healing and tissue regeneration markets, further positioning Ceapro in dermatology.